Print E-mail
Volume 42, Number 5, October 2009

 Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillintazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia

Kao-Pin Hwang, Ya-Fen Tang, Yea-Huei Shen

Received: September 2, 2008    Revised: April 16, 2008    Accepted: June 16, 2008   


Corresponding author:

Dr. Yea-Huei Shen, Infection Control Committee, Yuan General Hospital, 162 Cheng-Kung 1st Rd., Kaohsiung, Taiwan.





Background and purpose: 


 To compare the antimicrobial activities of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common organisms that cause communityacquired bacteremia and to identify the most active agents for the treatment of extended-spectrum β-lactamase (ESBL)–producingEscherichia coli and Klebsiella pneumoniae




1200 blood specimens from patients with community-acquired bacteremia were collected at Chang Gung Memorial Hospital, Kaohsiung, Taiwan. All isolates were identified by the API system, and each culture’s antimicrobial susceptibility was determined by the standard disk-diffusion method. The minimal inhibitory concentrations of the antibiotics were detected by the Epsilimeter test.





   The in vitro susceptibilities of 11 of the 12 common pathogens to ertapenem were 100%. The frequency of ESBL-producing E. coli and K. pneumoniae was 6.2% and 9.5%, respectively. Only 48% and 50% of E. coliand K. pneumoniae, respectively, were susceptible to ciprofloxacin. These data infer that ciprofloxacin should not be given for ESBL-producing E. coli and K. pneumoniae. Ceftriaxone and piperacillin-tazobactam had high activity against the most common pathogens isolated



 ESBL E. coli and K. pneumoniae are highly resistant to ciprofloxacin, so this antibiotic should be avoided for patients with community-acquired bacteremia. ESBL E. coli and K. pneumoniae are highly susceptible to ertapenem